Jump Financial LLC Decreases Holdings in UroGen Pharma Ltd. (NASDAQ:URGN)

Jump Financial LLC lowered its position in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 69.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,185 shares of the company's stock after selling 39,265 shares during the period. Jump Financial LLC owned about 0.07% of UroGen Pharma worth $183,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Rosalind Advisors Inc. bought a new stake in shares of UroGen Pharma in the 4th quarter valued at about $9,266,000. Geode Capital Management LLC lifted its position in UroGen Pharma by 1.4% during the fourth quarter. Geode Capital Management LLC now owns 461,902 shares of the company's stock valued at $4,919,000 after acquiring an additional 6,265 shares during the last quarter. Wells Fargo & Company MN lifted its position in UroGen Pharma by 2.7% during the fourth quarter. Wells Fargo & Company MN now owns 221,540 shares of the company's stock valued at $2,359,000 after acquiring an additional 5,801 shares during the last quarter. Alliancebernstein L.P. lifted its position in UroGen Pharma by 751.5% during the fourth quarter. Alliancebernstein L.P. now owns 199,259 shares of the company's stock valued at $2,122,000 after acquiring an additional 175,859 shares during the last quarter. Finally, Wellington Management Group LLP lifted its position in UroGen Pharma by 7.0% during the fourth quarter. Wellington Management Group LLP now owns 146,953 shares of the company's stock valued at $1,565,000 after acquiring an additional 9,653 shares during the last quarter. Hedge funds and other institutional investors own 91.29% of the company's stock.

Insider Transactions at UroGen Pharma

In other news, insider Mark Schoenberg sold 4,551 shares of the stock in a transaction on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the sale, the insider now owns 145,666 shares in the company, valued at $1,622,719.24. This represents a 3.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Jason Drew Smith sold 7,379 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the sale, the general counsel now owns 26,468 shares in the company, valued at $294,853.52. The trade was a 21.80 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.10% of the company's stock.

Analysts Set New Price Targets

URGN has been the subject of a number of analyst reports. Guggenheim reissued a "buy" rating on shares of UroGen Pharma in a research report on Tuesday. The Goldman Sachs Group decreased their target price on shares of UroGen Pharma from $22.00 to $16.00 and set a "neutral" rating for the company in a research report on Thursday, April 17th. D. Boral Capital reissued a "buy" rating and set a $25.00 target price on shares of UroGen Pharma in a research report on Monday. HC Wainwright reissued a "buy" rating and set a $55.00 target price on shares of UroGen Pharma in a research report on Monday. Finally, LADENBURG THALM/SH SH assumed coverage on shares of UroGen Pharma in a research note on Wednesday, February 19th. They set a "buy" rating and a $31.00 price target on the stock. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $32.86.

UroGen Pharma Stock Performance

UroGen Pharma stock traded down $0.23 during mid-day trading on Thursday, reaching $11.41. 534,142 shares of the company traded hands, compared to its average volume of 532,008. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. UroGen Pharma Ltd. has a fifty-two week low of $8.94 and a fifty-two week high of $20.70. The company has a market capitalization of $525.93 million, a price-to-earnings ratio of -3.62 and a beta of 0.80. The firm's fifty day moving average is $10.47 and its two-hundred day moving average is $11.08.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last released its quarterly earnings data on Monday, March 10th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.11). The firm had revenue of $24.57 million for the quarter, compared to analysts' expectations of $25.25 million. On average, equities research analysts expect that UroGen Pharma Ltd. will post -3.12 earnings per share for the current fiscal year.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.